Manufacturing problems persist for Aurobindo, U.S.' second-largest generics producer
admin 9th April 2019 Uncategorised 0When Aurobindo forked over $1 billion to snap up some of Novartis’ unwanted drugs last year, it set the Indian drugmaker up to be the second-largest generics player in the U.S. But it is one that brings a history of quality issues when it comes to manufacturing, as exemplified in the latest thrashing by the FDA.
More: Manufacturing problems persist for Aurobindo, U.S.' second-largest generics producer
Source: fierce